|Other Names||Apoptosis inhibitor 5, API-5, Antiapoptosis clone 11 protein, AAC-11, Cell migration-inducing gene 8 protein, Fibroblast growth factor 2-interacting factor, FIF, Protein XAGL, API5|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Antiapoptotic factor that may have a role in protein assembly. Negatively regulates ACIN1. By binding to ACIN1, it suppresses ACIN1 cleavage from CASP3 and ACIN1-mediated DNA fragmentation. Also known to efficiently suppress E2F1-induced apoptosis. Its depletion enhances the cytotoxic action of the chemotherapeutic drugs.|
|Cellular Location||Nucleus. Cytoplasm. Note=Mainly nuclear. Can also be cytoplasmic|
|Tissue Location||Expressed in all tissues tested, including heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Highest levels in heart, pancreas and placenta. Highly expressed in several cancers. Preferentially expressed in squamous cell carcinoma versus adenocarcinoma in non-small cell lung cancer.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Antiapoptotic factor that may have a role in protein assembly. Negatively regulates ACIN1. By binding to ACIN1, it suppresses ACIN1 cleavage from CASP3 and ACIN1-mediated DNA fragmentation. Also known to efficiently suppress E2F1-induced apoptosis. Its depletion enhances the cytotoxic action of the chemotherapeutic drugs.
Wang, Z., et al. Med. Sci. Monit. 16 (8), CR357-CR364 (2010) :Ren, K., et al. Pathol. Oncol. Res. 16(2):229-237(2010)Need, A.C., et al. Hum. Mol. Genet. 18(23):4650-4661(2009)Rigou, P., et al. EMBO J. 28(11):1576-1588(2009)Wang, Y., et al. J. Biol. Chem. 283(19):13205-13215(2008)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.